GLP-1 Peptide Atlas, by Delfa

CompletedPhase 1

A Study of LY3841136 in Japanese Participants With Obesity or Overweight

A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3841136 Monotherapy, and LY3841136 in Combination With Tirzepatide, in Japanese Participants With Obesity or Overweight

Lead sponsor

Eli Lilly and Company

Assets

Eloralintide / Tirzepatide

Listed sites

Recruiting sites

—

Enrollment

128

actual

Study population

Obesity / overweight

Key I/E criterion

•BMI 27-40

Primary endpoint

•Serious AEs (any)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06297616

Org study ID18814

Secondary IDJ3R-JE-YDABEli Lilly and Company

Timeline

Milestones

Study first posted2024-03-07actual

Study start2024-04-15actual

Primary completion2025-11-21actual

Study completion2025-11-21actual

Last update posted2026-01-16actual

Assets

Investigational agents

Eloralintide Tirzepatide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

Maximum age65 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Male or female participants who agree to contraception requirements

•Have a body mass index (BMI) within the range of 27 to 40 kg/m², inclusive

•Have had a stable weight for the 3 months

Exclusion criteria

•Have a history of significant atopy (severe allergic manifestations), multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions

•Have a history or presence of psychiatric disorders, including a history of major depressive disorder or severe psychiatric disorders such as schizophrenia, bipolar disorder within the last 3 years

•Have been diagnosed with Type 1 or Type 2 Diabetes Mellitus

•Have a history of chronic medical conditions involving the heart, liver, or kidneys

•Have a history of any malignancy within the past 5 years

•Have a history or presence of a GI disorder

•Have had within the last 6 months, or plan to have during the study, a device-based or surgical treatment use for obesity

•Have been treated, or plan to be treated, with prescription medications or other non-approved drugs intended to promote weight loss, within 3 months prior to screening

•For participants in Part B, have previously received tirzepatide within 6 months prior to screening

•For participants in Part B, have a personal or family history of medullary thyroid carcinoma, or have multiple endocrine neoplasia syndrome type 2

Endpoints (8)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK

Weight & body composition

2 endpoints

Secondary/protocol endpoint

Part A Pharmacodynamics (PD): Change From Baseline in Body Weight at Week 12

Time frame:Baseline through Week 12

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Part B PD: Change From Baseline in Body Weight at Week 24

Time frame:Baseline through Week 24

Body weight, absolute change (kg)

change from baseline, improvement

Safety / tolerability / PK

6 endpoints

Primary/protocol endpoint

Part A: Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration at Week 22

Time frame:Baseline through Week 22

Serious AEs (any)

event count, event

Primary/protocol endpoint

Part B: Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration at Week 34

Time frame:Baseline through Week 34

Serious AEs (any)

event count, event

Secondary/protocol endpoint

Part A Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3841136

Time frame:Predose through Week 22

AUC₀–∞

concentration, descriptive

Secondary/protocol endpoint

Part A PK: Maximum Observed Concentration (Cmax) of LY3841136

Time frame:Predose through Week 22

Cmax

concentration, descriptive

Secondary/protocol endpoint

Part B PK: AUC of LY3841136 in Combination with Tirzepatide

Time frame:Predose through Week 34

AUC₀–∞

concentration, descriptive

Secondary/protocol endpoint

Part B PK: Cmax of LY3841136 in Combination with Tirzepatide

Time frame:Predose through Week 34

Cmax

concentration, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.